Código QR (código de barras bidimensional)

Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance

Trastuzumab (T) and tyrosine kinase inhibitors (TKIs) are among the first-line treatments recommended for HER2-positive breast cancer. More recently, antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have been authorized, and they represent the...

Fuld beskrivelse

Na minha lista:
Principais autores: Claudiu Morgovan, Carmen Maximiliana Dobrea, Anca Butuca, Anca Maria Arseniu, Adina Frum, Luca Liviu Rus, Adriana Aurelia Chis, Anca Maria Juncan, Felicia Gabriela Gligor, Cecilia Georgescu, Steliana Ghibu, Andreea Loredana Vonica-Tincu
Format: Artigo
Sprog:Inglês
Udgivet: MDPI AG 2024-04-01
Serier:Biomedicines
Fag:
trastuzumab emtansine
trastuzumab deruxtecan
antibody-drug conjugates
HER2-positive breast cancer
HER2-targeted therapy
adverse reactions
Online adgang:https://www.mdpi.com/2227-9059/12/5/953
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker